Comparative Pharmacology
Head-to-head clinical analysis: LIBRAX versus QUARZAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRAX versus QUARZAN.
LIBRAX vs QUARZAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlordiazepoxide is a benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression. Clidinium is an anticholinergic that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretions.
Quarzan (clidinium bromide) is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretion.
1-2 capsules orally 3-4 times daily (each capsule contains chlordiazepoxide 5 mg and clidinium 2.5 mg).
5 mg orally twice daily, with or without food.
None Documented
None Documented
Chlordiazepoxide: 5-30 hours (terminal half-life; increases with age, liver disease; active metabolite desmethyldiazepam has half-life 30-200 hours). Clidinium: 3-4 hours.
Terminal elimination half-life is approximately 10-14 hours; allows twice-daily dosing with steady state reached in 2-3 days.
Chlordiazepoxide (CDX): Renal (1-2% unchanged, 4-6% as metabolites), biliary/fecal (minor). Clidinium bromide: Fecal (50-60% as unchanged drug), renal (40-50% as metabolites and unchanged).
Primarily renal excretion of unchanged drug (50-70%) and its active metabolite; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Antispasmodic
Antispasmodic